Mirum Pharmaceuticals, INC Form 4 insider transactions

Eric Bjerkhult, CFO of Mirum Pharmaceuticals, reports the acquisition of 470 shares of common stock through the company's Employee Stock Purchase Plan on May 10, 2024.

Christopher Peetz, CEO of Mirum Pharmaceuticals, acquired 817 shares of common stock through the company's Employee Stock Purchase Plan on May 10, 2024.

Pamela Vig, Chief Scientific Officer of Mirum Pharmaceuticals, acquired 94 shares of common stock through the company's Employee Stock Purchase Plan on May 10, 2024.

Eric Bjerkholt, CFO of Mirum Pharmaceuticals, recently purchased 2,000 shares of the company's common stock at $24.80 per share.

Peter Radovich, President and COO of Mirum Pharmaceuticals, sold 4,303 shares of common stock on March 25, 2024.

Peter Radovich, President and COO of Mirum Pharmaceuticals, sold 1,379 shares of common stock on January 9, 2023, to cover tax withholding obligations related to vesting restricted stock units.

Pamela Vig, Chief Scientific Officer of Mirum Pharmaceuticals, reports selling 1,379 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Lara Longpre, Chief Development Officer of Mirum Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Mirum Pharmaceuticals CEO Christopher Peetz sold 5,159 shares of common stock on January 9, 2023, to cover tax withholding obligations associated with the vesting of restricted stock units.

Eric Bjerkhult, CFO of Mirum Pharmaceuticals, reports purchasing 2,000 shares of common stock at $25.80 per share on March 18, 2024.